

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:


Lola WEISS et al

Serial No.: 10/589,623

Filed: August 16, 2006

For: TREATING OR PREVENTING DIABETES  
WITH CANNABIDIOL

Examiner: Not Yet Assigned



Group Art Unit: 1614

Attorney  
Docket: 32361

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan  
Registration No. 40,338

Dated: June 20, 2007

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**


*(use as many sheets as necessary)*

Sheet 1 of 3

Sheet 1 of 3 Attorney Docket Number

U. S. PATENT DOCUMENTS

JUN 29 2007



## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	11	PCT WO 00/19773	06-6-2000	Kochman et al.		
	12	PCT WO 98/41519	09-24-1998	Bender et al.		
	13	PCT WO 97/29079	08-14-1997	Inaba et al.		
	14	PCT WO 94/12466	09-9-1994	Mechoulam et al.		
	15	PCT WO 99/02499	01-21-1999	Inaba et al.		
	16	EP 0444451	04-4-1991	D'Ambra et al.		
	17	EP 0570920	11-24-1993	Mechoulam et al.		
	18	FR 2735774	09-12-1997	Rinaldi et al.		

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the grant of the Japanese patent must precede the serial number of the patent document. <sup>5</sup> Kind of document

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.  
**SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet 2 Of 3 Attorney Docket Number 32361

Complete if Known

Application Number	10/589,623
Filing Date	August 16, 2006
First Named Inventor	Lola WEISS et al
Group Art Unit	1614
Examiner Name	Not Yet Assigned

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	19	Adams et al. "Isolation of Cannabinol, Cannabidiol and Quebrachitol From Red Oil of Minnesota Wild Hemp", Journal of the American Chemical Society, 62: 2194-2196, 1940.	
	20	Burstein et al. "Synthetic Nonpsychotropic Cannabinoids With Potent Antiinflammatory, Analgesic, and Leukocyte Antiadhesion Activities", Journal of Medicinal Chemistry, 35: 3135-3141, 1992.	
	21	Coffey et al. "Tetrahydrocannabinol Inhibition of Macrophage Nitric Oxide Production", Biochemical Pharmacology, 52: 743-751, 1996.	
	22	Devane et al. "Isolation and Structure of A Brain Constituent That Binds to the Cannabinoid Receptor", Science, 258: 1946-1949, 1992.	
	23	Edery et al. "Structural Requirements for Cannabinoid Activity", Annals of the NY Academy of Sciences, 191: 40-53, 1971.	
	24	Felder et al. "Anandamide, An Endogenous Cannabinimimetic Eicosanoid, Binds to the Cloned Human Cannabinoid Receptor and Stimulates Receptor-Mediated Signal Transduction", Proc. Natl. Acad. Sci. USA, 90: 7656-7660, 1993.	
	25	Gaoni et al. "The Isolation and Structure of Δ <sup>1</sup> -Tetrahydrocannabinol and Other Neutral Cannabinoids From Hashish", Journal of the American Chemical Society, 93: 217-224, 1971.	
	26	Hanuš et al. "Two New Unsaturated Fatty Acid Ethanolamides in Brain That Bind to the Cannabinoid Receptor", Journal of Medicinal Chemistry, 36: 3032-3034, 1993.	
	27	Hanuš et al. "2-Arachidonyl Glyceryl Ether, An Endogenous Agonist of the Cannabinoid CB1 Receptor", Proc. Natl. Acad. Sci. USA, 98(7): 3662-3665, 2001.	
	28	Houry et al. "Benzoxocin and Benzoxonin Derivatives. Novel Groups of Terpenophenols With Central Nervous System Activity. A Correction", Journal of Medicinal Chemistry, 18(9): 951-952, 1975.	
	29	Zuardi et al. "Antipsychotic Effect of Cannabidiol", Journal of Clinical Psychiatry, 56(10): 485-486, 1995.	
	30	Formukong et al. "Analgesic and Antiflammatory Activity of Constituents of Cannabis Sativa L.", Inflammation, 12(4): 361-371, 1988.	
	31	Venstrom et al. "Survival After Pancreas Transplantation in Patients With Diabetes and Preserved Kidney Function", JAMA, 290(21): 2817-2823, 2003. Correction: 291(13): 1566, 2004.	
	32	Kendall et al. "Pancreas and Islet Transplantation", The Endocrinologist, 5: 28-35, 1995.	
	33	Mechoulam "Marijuana: Chemistry, Pharmacology, Metabolism and Clinical Effects", Academic Press, 65: Book Info & Table of Contents, 1973.	
	34	Houry et al. "Benzoxocin and Benzoxonin Derivatives. Novel Groups of Terpenophenols With Central Nervous System Activity", Journal of Medicinal Chemistry, 17(3): 287-293, 1974.	

Signature	Considered
-----------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Complete if Known	
Application Number	10/589,623
Filing Date	August 16, 2006
First Named Inventor	Lola WEISS et al
Group Art Unit	1614
Examiner Name	Not Yet Assigned

Sheet	3	Of	3	Attorney Docket Number	32361
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	35	Mechoulam et al. "Hashish - I. The Structure of Cannabidiol", Tetrahedron, 19: 2073-2078, 1963.			
	36	Mechoulam et al. "Identification of An Endogenous 2-Monoglyceride, Present in Canine Gut, That Binds to Cannabinoid Receptors", Biochemical Pharmacology, 50(1): 83-90, 1995.			
	37	Mechoulam et al. "Recent Advances in the Chemistry and Biochemistry of Cannabis", Chemical Reviews, 76(1): 75-112, 1976.			
	38	Mechoulam et al. "Synthesis and Biological Activity of Five Tetrahydrocannabinol Metabolites", Journal of the American Chemical Society, 94(22): 7930-7931, 1972.			
	39	Mechoulam et al. "Stereochemical Requirements for Cannabinoid Activity", Journal of Medicinal Chemistry, 23(10): 1068-1072, 1980;			
	40	Mechoulam et al. "Chemical Basis of Hashish Activity", Science, 169(3945): 611-612, 1970.			
	41	Mechoulam et al. "Synthesis of the Individual, Pharmacologically Distinct, Enantiomers of A Tetrahydrocannabinol Derivative", Tetrahedron: Asymmetry, 1(5): 315-318, 1990.			
	42	Murphy et al. "Cannabinoid Geometry and Biological Activity", Marijuana/Cannabinoids: Neurobiology and Neurophysiology, P.1-33, 1992.			
	43	Leite et al. "Anticonvulsant Effects of the ( - ) and ( + )Isomers of Cannabidiol and Their Dimethylheptyl Homologs", Pharmacology, 24: 141-146, 1982.			
	44	Zuardi et al. "Effects of Cannabidiol in Animal Models Predictive of Antipsychotic Activity", Psychopharmacology, 104(2): 260-264, 1991.			
	45	Rhee et al. "Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibition of Adenylylcyclase", Journal of Medicinal Chemistry, 40: 3228-3233, 1997.			
	46	Robertson "Seminars in Medicine of the Beth Israel Hospital, Boston: Pancreatic and Islet Transplantation for Diabetes - Cures of Curiosities?", The New England Journal of Medicine, 327(26): 1861-1868,			
	47	Petrzilka et al. "Synthese und Chiralität des ( - )-Cannabidiols", Helvetica Chimica Acta, 50, Fasciculus 2(73-74/Chap.74): 719-723, 1967.			
	48	Sheskin et al. "Structural Requirements for Binding of Anandamide-Type Compounds to the Brain Cannabinoid Receptor", Journal of Medicinal Chemistry, 40: 659-667, 1997.			
	49	Srebnik et al. "Base-Catalysed Double-Bond Isomerizations of Cannabinoids: Structural and Stereochemical Aspects", Journal of the Chemical Society, Perkin Transactions I, P.2881-2886, 1984.			

Signature	Considered
-----------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Signature	Considered
-----------	------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).  2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.